AN2 Therapeutics, Inc.ANTXNASDAQ
Loading
Year-over-year SG&A expense growth
| Period | Value |
|---|---|
| Q4 2025 | -19.84% |
| Q3 2025 | -24.30% |
| Q2 2025 | 4.39% |
| Q1 2025 | 19.84% |
| Q4 2024 | -7.86% |
| Q3 2024 | -6.62% |
| Q2 2024 | 2.47% |
| Q1 2024 | -6.55% |
| Q4 2023 | 3.87% |
| Q3 2023 | 22.46% |
| Q2 2023 | -24.44% |
| Q1 2023 | 8.86% |
| Q4 2022 | 11.43% |
| Q3 2022 | -8.06% |
| Q2 2022 | 77.32% |
| Q1 2022 | 15.04% |
| Q4 2021 | 12.29% |
| Q3 2021 | 76.73% |
| Q2 2021 | 123.94% |
| Q1 2021 | 0.00% |